Smoking Cessation-Epidemiology Forecast–2030

Best Price Guarantee	Length	Publisher	Published Date	SKU
from $3,750	80 Pages	DelveInsight	January, 2021	DEL16484995

Best Price Guarantee
Price	from $3,750
Length	80 Pages
Publisher	DelveInsight
Published Date	January, 2021
SKU	DEL16484995

DelveInsight’s ‘Smoking Cessation-Epidemiology Forecast–2030’ report delivers an in-depth understanding of the smoking cessation, historical and forecasted epidemiology as well as the smoking cessation trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Smoking Cessation Understanding
Smoking cessation is the process of discontinuing tobacco smoking. When a person smokes tobacco in cigarettes, cigars or pipes, they absorb toxins that can lead to various health problems such as diabetes, cancer, chronic obstructive pulmonary disease (COPD), heart diseases, lung diseases, etc.

The main barrier to smoking cessation is nicotine addiction. Some of the most common nicotine withdrawal symptoms smokers face when they try to quit smoking include craving for smoking, mood swings, insomnia, constipation, increased appetite, anxiety, etc.

Smoking Cessation Symptoms
Stopping smoking brings about a variety of symptoms associated with physical and psychological withdrawal. Most symptoms decrease sharply during the first few days of quitting, followed by a continued, but slower rate of decline in the second and third week of abstinence. For some people, coping with withdrawal symptoms is like “riding a roller coaster”—there may be sharp turns, slow climbs, and unexpected plunges. Most symptoms pass within 2–4 weeks after stopping.
Continued in the report…..
Smoking Cessation Epidemiology Perspective by DelveInsight
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Diagnosed Prevalent Cases of Smokers, Gender-specific Diagnosed Prevalent Cases of Smokers, Age-specific Diagnosed Prevalent Cases of Smokers and Total Diagnosed Prevalent Cases of Smoking Cessation in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2017 to 2030.

Smoking Cessation Detailed Epidemiology Segmentation
• The total diagnosed prevalent population of Smoking Cessation in the 7MM was 49,301,950 in 2017.
• The United States showed the highest diagnosed prevalent cases of smokers, as compared to EU5, and Japan. In 2017, the number of smokers in the US was estimated to be 35,288,932.
• In the US, there were 19,303,046 diagnosed prevalent cases of smokers among males and 15,985,886 diagnosed prevalent cases among females in 2017.
• Out of the total 35,288,932 diagnosed prevalent cases of smokers in the US, the highest cases were observed in the age group 45–64 years (14,080,284) and the least cases were observed in 18-24 years (3,140,715) in the year 2017.
• Among the European-5 countries, Germany had the highest diagnosed prevalent population of smokers with 19,305,099 cases, followed by France with 14,044,812 cases. On the other hand, the United Kingdom had the lowest diagnosed prevalent population of 7,750,777 in 2017.
• Japan had 19,411,835 diagnosed prevalent cases of smokers in 2017 and out of this approximately 5,610,020 diagnosed cases of smoking cessation were estimated.

Scope of the Report
• The report covers a descriptive overview of smoking cessation, explaining symptoms of nicotine withdrawal and barriers to smoking cessation.
• The report provides insight into the 7MM historical and forecasted patient pool covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
• The report assesses the disease risk and burden and highlights the unmet needs of smoking cessation.
• The report helps to recognize the growth opportunities in the 7MM with respect to the patient population.
• The report provides the segmentation of the disease epidemiology for 7MM by Total Diagnosed Prevalent Cases of Smokers, Gender-specific Diagnosed Prevalent Cases of Smokers, Age-specific Diagnosed Prevalent Cases of Smokers, and Total Diagnosed Prevalent Cases of Smoking Cessation.

Report Highlights
• 11-Year Forecast of Smoking Cessation
• 7MM Coverage
• Total Diagnosed Prevalent Cases of Smoking Cessation
• Gender-specific Diagnosed Prevalent Cases of Smoking Cessation
• Age-specific Diagnosed Prevalent Cases of Smoking Cessation
• Total Diagnosed Prevalent Cases of Smoking Cessation

Key Questions Answered
• What are the disease risk, burdens, and unmet needs of Smoking Cessation?
• What is the historical Smoking Cessation patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK), and Japan?
• What would be the forecasted patient pool of Smoking Cessation at the 7MM level?
• What will be the growth opportunities across the 7MM with respect to the patient population pertaining to Smoking Cessation?
• Out of the above-mentioned countries, which country would have the highest diagnosed prevalent population of Smoking Cessation during the forecast period (2020–2030)?
• At what CAGR the population is expected to grow across the 7MM during the forecast period (2020–2030)?

Reasons to buy
The Smoking Cessation report will allow the user to -
• Develop business strategies by understanding the trends shaping and driving the 7MM Smoking Cessation epidemiology forecast.
• The Smoking Cessation epidemiology report and model were written and developed by Masters and Ph.D. level epidemiologists.
• The Smoking Cessation epidemiology model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over the eleven-year forecast period using reputable sources.

Key Assessments
• Patient Segmentation
• Disease Risk and Burden
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population
Geographies Covered
• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan
Study Period: 2017–2030

1. Key Insights
2. Executive Summary of Smoking Cessation
3. Smoking Cessation Epidemiology Overview at a Glance: 3.1. Total Epidemiology Share (%) Distribution of Smoking Cessation in 2017; 3.2. Total Epidemiology Share (%) Distribution of Smoking Cessation in 2030
4. Disease Background and Overview: Smoking Cessation: 4.1. Introduction; 4.2. Symptoms of Nicotine Withdrawal; 4.3. Barriers to Smoking Cessation; 4.3.1. Addiction; 4.3.2. Fear of weight gain; 4.3.3. Depression
5. Epidemiology and Patient Population: 5.1. Key Findings; 5.2. KOL Views; 5.3. Epidemiology Methodology; 5.4. Total Diagnosed Prevalent Cases of Smokers in the 7MM; 5.5. Total Diagnosed Prevalent Cases of Smoking Cessation in the 7MM
6. United States Epidemiology: 6.1. Assumptions and Rationale; 6.2. Total Diagnosed Prevalent Cases of Smokers in the United States; 6.3. Gender-specific Diagnosed Prevalent Cases of Smokers in the United States; 6.4. Age-specific Diagnosed Prevalent Cases of Smokers in the United States; 6.5. Total Diagnosed Prevalent Cases of Smoking Cessation in the United States
7. EU5 Epidemiology: 7.1. Germany Epidemiology; 7.1.1. Assumptions and Rationale; 7.1.2. Total Diagnosed Prevalent Cases of Smokers in Germany; 7.1.3. Gender-specific Diagnosed Prevalent Cases of Smokers in Germany; 7.1.4. Age-specific Diagnosed Prevalent Cases of Smokers in Germany; 7.1.5. Total Diagnosed Prevalent Cases of Smoking Cessation in Germany; 7.2. France Epidemiology; 7.2.1. Assumptions and rationale; 7.2.2. Total Diagnosed Prevalent Cases of Smokers in France; 7.2.3. Gender-specific Diagnosed Prevalent Cases of Smokers in France; 7.2.4. Age-specific Diagnosed Prevalent Cases of Smokers in France; 7.2.5. Total Diagnosed Prevalent Cases of Smoking Cessation in France; 7.3. Italy Epidemiology; 7.3.1. Assumptions and Rationale; 7.3.2. Total Diagnosed Prevalent Cases of Smokers in Italy; 7.3.3. Gender-specific Diagnosed Prevalent Cases of Smokers in Italy; 7.3.4. Age-specific Diagnosed Prevalent Cases of Smokers in Italy; 7.3.5. Total Diagnosed Prevalent Cases of Smoking Cessation in Italy; 7.4. Spain Epidemiology; 7.4.1. Assumptions and Rationale; 7.4.2. Total Diagnosed Prevalent Cases of Smokers in Spain; 7.4.3. Gender-specific Diagnosed Prevalent Cases of Smokers in Spain; 7.4.4. Age-specific Diagnosed Prevalent Cases of Smokers in Spain; 7.4.5. Total Diagnosed Prevalent Cases of Smoking Cessation in Spain; 7.5. United Kingdom Epidemiology; 7.5.1. Assumptions and Rationale; 7.5.2. Total Diagnosed Prevalent Cases of Smokers in the United Kingdom; 7.5.3. Gender-specific Diagnosed Prevalent Cases of Smokers in the United Kingdom; 7.5.4. Age-specific Diagnosed Prevalent Cases of Smokers in the United Kingdom; 7.5.5. Total Diagnosed Prevalent Cases of Smoking Cessation in the UK
8. Japan Epidemiology: 8.1. Assumptions and Rationale; 8.2. Total Diagnosed Prevalent Cases of Smokers in Japan; 8.3. Gender-specific Diagnosed Prevalent Cases of Smokers in Japan; 8.4. Age-specific Diagnosed Prevalent Cases of Smokers in Japan; 8.5. Total Diagnosed Prevalent Cases of Smoking Cessation in Japan
9. Appendix: 9.1.Bibliography; 9.2.Report Methodology
10. DelveInsight Capabilities
11. Disclaimer
12. About DelveInsight: Table 1 Summary of Smoking Cessation Epidemiology and Key Events (2017–2030); Table 2 Total Diagnosed Prevalent Cases of Smokers in the 7MM (2017–2030); Table 3 Total Diagnosed Prevalent Cases of Smoking Cessation in the 7MM (2017–2030); Table 4 Total Diagnosed Prevalent Cases of Smokers in the US (2017–2030); Table 5 Gender-specific Diagnosed Prevalent Cases of Smokers in the US (2017–2030); Table 6 Age-specific Diagnosed Prevalent Cases of Smokers in the US (2017–2030); Table 7 Total Diagnosed Prevalent Cases of Smoking Cessation in the US (2017–2030); Table 8 Total Diagnosed Prevalent Cases of Smokers in Germany (2017–2030); Table 9 Gender-specific Diagnosed Prevalent Cases of Smokers in Germany (2017–2030); Table 10 Age-specific Diagnosed Prevalent Cases of Smokers in Germany (2017–2030); Table 11 Total Diagnosed Prevalent Cases of Smoking Cessation in Germany (2017–2030); Table 12 Total Diagnosed Prevalent Cases of Smokers in France (2017–2030); Table 13 Gender-specific Diagnosed Prevalent Cases of Smokers in France (2017–2030); Table 14 Age-specific Diagnosed Prevalent Cases of Smokers in France (2017–2030); Table 15 Total Diagnosed Prevalent Cases of Smoking Cessation in France (2017–2030); Table 16 Total Diagnosed Prevalent Cases of Smokers in Italy (2017–2030); Table 17 Gender-specific Diagnosed Prevalent Cases of Smokers in Italy (2017–2030); Table 18 Age-specific Diagnosed Prevalent Cases of Smokers in Italy (2017–2030); Table 19 Total Diagnosed Prevalent Cases of Smoking Cessation in Italy (2017–2030); Table 20 Total Diagnosed Prevalent Cases of Smokers in Spain (2017–2030); Table 21 Gender-specific Diagnosed Prevalent Cases of Smokers in Spain (2017–2030); Table 22 Age-specific Diagnosed Prevalent Cases of Smokers in Spain (2017–2030); Table 23 Total Diagnosed Prevalent Cases of Smoking Cessation in Spain (2017–2030); Table 24 Total Diagnosed Prevalent Cases of Smokers in the UK (2017–2030); Table 25 Gender-specific Diagnosed Prevalent Cases of Smokers in the UK (2017–2030); Table 26 Age-specific Diagnosed Prevalent Cases of Smokers in the UK (2017–2030); Table 27 Total Diagnosed Prevalent Cases of Smoking Cessation in the UK (2017–2030); Table 28 Total Diagnosed Prevalent Cases of Smokers in Japan (2017–2030); Table 29 Gender-specific Diagnosed Prevalent Cases of Smokers in Japan (2017–2030); Table 30 Age-specific Diagnosed Prevalent Cases of Smokers in Japan (2017–2030); Table 31 Total Diagnosed Prevalent Cases of Smoking Cessation in Japan (2017–2030); Figure 1 Stages of the addiction cycle; Figure 2 Tobacco and Cancer; Figure 3 KOL Views; Figure 4 Total Diagnosed Prevalent Cases of Smokers in the 7MM (2017–2030); Figure 5 Total Diagnosed Prevalent Cases of Smoking Cessation in the 7MM (2017–2030); Figure 6 Total Diagnosed Prevalent Cases of Smokers in the US (2017–2030); Figure 7 Gender-specific Diagnosed Prevalent Cases of Smokers in the US (2017–2030); Figure 8 Age-specific Diagnosed Prevalent Cases of Smokers in the US (2017–2030); Figure 9 Total Diagnosed Prevalent Cases of Smoking Cessation in the US (2017–2030); Figure 10 Total Diagnosed Prevalent Cases of Smokers in Germany (2017–2030); Figure 11 Gender-specific Diagnosed Prevalent Cases of Smokers in Germany (2017–2030); Figure 12 Age-specific Diagnosed Prevalent Cases of Smokers in Germany (2017–2030); Figure 13 Total Diagnosed Prevalent Cases of Smoking Cessation in Germany (2017–2030); Figure 14 Total Diagnosed Prevalent Cases of Smokers in France (2017–2030); Figure 15 Gender-specific Diagnosed Prevalent Cases of Smokers in France (2017–2030); Figure 16 Age-specific Diagnosed Prevalent Cases of Smokers in France (2017–2030); Figure 17 Total Diagnosed Prevalent Cases of Smoking Cessation in France (2017–2030); Figure 18 Total Diagnosed Prevalent Cases of Smokers in Italy (2017–2030); Figure 19 Gender-specific Diagnosed Prevalent Cases of Smokers in Italy (2017–2030); Figure 20 Age-specific Diagnosed Prevalent Cases of Smokers in Italy (2017–2030); Figure 21 Total Diagnosed Cases of Smoking Cessation in Italy (2017–2030); Figure 22 Total Diagnosed Prevalent Cases of Smokers in Spain (2017–2030); Figure 23 Gender-specific Diagnosed Prevalent Cases of Smokers in Spain (2017–2030); Figure 24 Age-specific Diagnosed Prevalent Cases of Smokers in Spain (2017–2030); Figure 25 Total Diagnosed Prevalent Cases of Smoking Cessation in Spain (2017–2030); Figure 26 Total Diagnosed Prevalent Cases of Smokers in the UK (2017–2030); Figure 27 Gender-specific Diagnosed Prevalent Cases of Smokers in the UK (2017–2030); Figure 28 Age-specific Diagnosed Prevalent Cases of Smokers in the UK (2017–2030); Figure 29 Total Diagnosed Prevalent Cases of Smoking Cessation in the UK (2017–2030); Figure 30 Total Diagnosed Prevalent Cases of Smokers in Japan (2017–2030); Figure 31 Gender-specific Diagnosed Prevalent Cases of Smokers in Japan (2017–2030); Figure 32 Age-specific Diagnosed Prevalent Cases of Smokers in Japan (2017–2030); Figure 33 Total Diagnosed Prevalent Cases of Smoking Cessation in Japan (2017–2030)